Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
129 hedge funds and large institutions have $455M invested in Intra-Cellular Therapies Inc. in 2016 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 26 reducing their positions, and 30 closing their positions.
225% more call options, than puts
Call options by funds: $6.09M | Put options by funds: $1.88M
92% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 26
7% more capital invested
Capital invested by funds: $425M → $455M (+$29.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 30
2% less funds holding
Funds holding: 132 → 129 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$17M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$13.3M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$6.4M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$3.66M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.14M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$5.13M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$4.45M |
| 4 |
Jennison Associates
New York
|
-$4.08M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$3.13M |
ITCI Hedge Fund Activity: Q4 2016 in Review
129 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2016, worth a combined $455M — up 6.9% from $425M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ITCI and 29 opened new positions — a net loss of 1 holder — while 26 trimmed existing stakes and 50 added.
The largest buyer was Citadel Advisors, adding an estimated $17M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $9.14M sold.
- 129 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2016, down from 132 in Q3 2016.
- Funds reported $455M of Intra-Cellular Therapies Inc. stock for Q4 2016, up 6.9% quarter-over-quarter.
- 29 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2016 and 30 closed out, a net change of -1 holder.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2016 was Citadel Advisors, an estimated $17M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2016 was Adage Capital Partners, an estimated $9.14M sold.
Based on aggregated 13F filings for Q4 2016.